Findings of a Study to Be Shared at Annual ASCO Meeting on June 4, 2012
A study focusing on outcomes involving imatinib (IM), the most commonly used drug in treating chronic myeloid leukemia (CML), is to be presented at the Annual American Society of Clinical Oncology Annual Meeting in Chicago on June 4, 2012. The study was undertaken by a group of researchers led by Dr. Eric Wu, Managing Principal at Analysis Group Inc., a leading provider of health care research and economic expertise.
The study concludes that a significant number of patients with CML receiving IM have been under-monitored, likely resulting in the under-detection of patients who experience a sub-optimal response to the treatment.
In "Monitoring and switching patterns in chronic myelogenous leukemia (CML) pts treated with imatinib (IM): A chart review analysis," the researchers1 studied CML patients selected from 29 community medical practices throughout the United States. Each physician reviewed and extracted up to 15 charts of CML patients in chronic phase treated with imatinib as first-line therapy. The research team measured monitoring patterns and patient response from a total of 297 patient charts against treatment milestones as defined by the National Comprehensive Cancer Network (NCCN) or the European LeukemiaNet (ELN) guidelines. Patients were followed from 0 up to 36 months. Among patients monitored, the percentage of patients that missed the milestone and switched to a second-line therapy was assessed. "We concluded from these assessments that there is considerable under-monitoring of CML patients receiving imatinib," states Dr. Wu. "This is likely to result in the under-detection of a suboptimal response to therapy in a significant portion of patients." The team also noted that the switching rate to a second-line therapy among patients who did not achieve an adequate response is much lower than suggested by either the NCCN or the ELN guidelines.
About Analysis Group
Analysis Group provides health outcomes research and economic consulting to leading corporations, organizations, and government agencies. The firm has more than 500 professionals, with offices in Boston, Chicago, Dallas, Denver, Los Angeles, Menlo Park, New York, San Francisco, Washington, and Montreal (www.analysisgroup.com).
1 Lei Chen, Annie Guerin, Clemence Aberki, Eric Q. Wu, Solveig Ericson, Elias Jabbour; Novartis Pharmaceuticals, East Hanover, NJ; Analysis Group, Inc., Boston, MA; University of Texas M. D. Anderson Cancer Center, Houston, TX.
Eileen Harrington, 617-425-8193